Petmed Express Inc SEC Filings

Douglas Krulik, Chief Accounting Officer of PetMed Express, Inc. (PETS), reported a non‑derivative equity grant on 09/09/2025. The filing shows a restricted stock award of 10,000 shares granted at a $0 purchase price under the companys 2024 Omnibus Incentive Plan. After the grant Mr. Krulik beneficially owns 50,000 shares. The award is scheduled to vest in full on the six‑month anniversary of the grant date provided he remains employed or in service, and the award also vests in full if the company terminates his service prior to full vesting unless the termination is for Cause. The Form 4 is signed by Mr. Krulik on 09/11/2025.

Douglas Krulik, Chief Accounting Officer of PetMed Express, Inc. (PETS), was granted 40,000 restricted stock units (RSUs) on 09/27/2024. The RSUs were issued under the Company’s 2024 Inducement Incentive Plan and vest in three equal annual installments — one-third on each of the first, second and third anniversaries of 09/27/2024 — subject to continued employment except as otherwise provided in the RSU agreement. Each RSU represents the right to receive one share of common stock upon vesting. Following the grant, Mr. Krulik is reported to beneficially own 40,000 shares directly. The Form 4 was signed by Mr. Krulik on 09/11/2025.

Douglas Krulik, identified as Chief Accounting Officer and a director of PetMed Express, Inc. (ticker: PETS), filed an Initial Statement of Beneficial Ownership (Form 3) reporting the event date of 08/19/2024. The filing states that no securities are beneficially owned by the reporting person. The form indicates it was filed by one reporting person and includes a manual signature dated 09/11/2025. The document provides the reporting person’s business address in Delray Beach, Florida, and confirms compliance with Section 16 reporting requirements through this submission.

PetMed Express insider purchase reported. Silvercape Investments Ltd filed a Form 4 showing it acquired 101,000 shares of PETS at $3.17 on 08/13/2025, increasing its direct beneficial ownership to 2,579,696 shares. The filing lists the reporting relationship as Director, shows transaction code P (purchase), and is signed by Peter Kennedy on 08/14/2025.

PetMed Express reported that on August 11, 2025 its Chief Executive Officer and President, Sandra Campos, and its Chief Financial Officer and Treasurer, Robyn D’Elia, resigned effective immediately. Under separation agreements the Company will continue each officer’s annual base salary for 13 months ($550,000 for Ms. Campos; $425,000 for Ms. D’Elia), reimburse COBRA premiums for 18 months, and accelerate pro‑rata vesting of certain restricted stock units while other equity awards will be forfeited. The Board reduced its size from six to five and appointed Leslie C.G. Campbell as Interim CEO and President and Doug Krulik as Interim Principal Financial Officer (while he continues as Chief Accounting Officer). The filing discloses an ongoing Audit Committee investigation into autoship revenue recognition, a $50 coupon promotion, and the company’s control environment; a press release was furnished as Exhibit 99.1.

PetMed Express, Inc. notified the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2025 because the company's Audit Committee investigation described in a Current Report filed July 1, 2025 remains incomplete.

The company says completion of that investigation is required to finish and file its Annual Report for the fiscal year ended March 31, 2025, which must be filed before the 10-Q. PetMed indicates a significant change in results is anticipated but cannot reasonably estimate amounts at this time. Contact: Robert Lawsky, General Counsel.